Olanzapine Disintegrating Tablets Clinical Trials

• A MULTICENTER, OPEN-LABEL, RANDOMIZED CROSSOVER TRIAL TO ASSESS SUBJECT PREFERENCE FOR ALPRAZOLAM ORALLY DISINTEGRATING TABLETS COMPARED TO CONVENTIONAL ALPRAZOLAM TABLETS IN SUBJECTS WITH ANXIETY
  ClinicalTrials.gov Identifier: NCT00139854 - Completed
  Anxiety
  
• An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.
  ClinicalTrials.gov Identifier: NCT00510211 - Recruiting
  Schizophrenia; Bipolar Disorder
  
• Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet
  ClinicalTrials.gov Identifier: NCT00324051 - Active, not recruiting
  Schizophrenia
  
• Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
  ClinicalTrials.gov Identifier: NCT00303602 - Active, not recruiting
  Schizophrenia; Schizoaffective Disorder; Bipolar Disorder
  
• Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects during the Maintenance Phase of Bipolar Illness
  ClinicalTrials.gov Identifier: NCT00071253 - Terminated
  Bipolar Disorder
  
• Oral Disintegrating Ondansetron Tablet to Reduce Vomiting from Gastroenteritis in a Pediatric Emergency Department
  ClinicalTrials.gov Identifier: NCT00120744 - Active, not recruiting
  Gastroenteritis; Vomiting; Diarrhea; Dehydration
  
• Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia
  ClinicalTrials.gov Identifier: NCT00320489 - Recruiting
  Schizophrenia
  
• A Multicenter, Open-Label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects with Stable Parkinson''s Disease
  ClinicalTrials.gov Identifier: NCT00139867 - Completed
  Parkinson''s Disease
  
• Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
  ClinicalTrials.gov Identifier: NCT00088465 - Active, not recruiting
  Schizophrenic Disorders
  
• A Controlled Study of Olanzapine in Children with Autism
  ClinicalTrials.gov Identifier: NCT00057408 - Recruiting
  Autistic Disorder
  
• Optimal Duration of Olanzapine Add-on Therapy in Major Depression
  ClinicalTrials.gov Identifier: NCT00568672 - Recruiting
  Relapse Rate of a Major Depressive Episode; Safety of Olanzapine in Subjects With Major Depression
  
• Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine
  ClinicalTrials.gov Identifier: NCT00259272 - Recruiting
  Bipolar Disorder I or II
  
• Glucose regulation during risperidone and olanzapine treatment
  ClinicalTrials.gov Identifier: NCT00006195 - Recruiting
  Schizophrenia
  
• Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-Release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain
  ClinicalTrials.gov Identifier: NCT00410943 - Active, not recruiting
  Pain
  
• PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets
  ClinicalTrials.gov Identifier: NCT00491998 - Recruiting
  Parkinson's Disease
  
• Comparison of Clozapine or Olanzapine in Childhood-Onset Psychotic Disorders
  ClinicalTrials.gov Identifier: NCT00001656 - Active, not recruiting
  Mental Disorder Diagnosed in Childhood; Psychotic Disorder; Schizophrenia
  
• A Study Comparing the Efficacy of Long-Acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
  ClinicalTrials.gov Identifier: NCT00236457 - Completed
  Schizophrenia; Psychotic Disorders
  
• A Randomized, Open-Label, Two-Way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects with Diabetic Gastroparesis
  ClinicalTrials.gov Identifier: NCT00139893 - Completed
  Diabetic gastroparesis
  
• Subcutaneous Olanzapine for Hyperactive or Mixed Delirium
  ClinicalTrials.gov Identifier: NCT00512291 - Active, not recruiting
  Advanced Cancer
  
• Pfizer/IVGTT/Ziprasidone/Olanzapine
  ClinicalTrials.gov Identifier: NCT00205725 - Active, not recruiting
  Schizophrenia; Type 2 Diabetes Mellitus
  
• Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents
  ClinicalTrials.gov Identifier: NCT00183612 - Active, not recruiting
  Bipolar Disorder; Psychotic Disorders
  
• Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
  ClinicalTrials.gov Identifier: NCT00443872 - Recruiting
  Parkinson's Disease
  
• A Study of Treatment Success in Changing From Olanzapine to Long-Acting Injectable Risperidone (RISPERDAL® CONSTA™)
  ClinicalTrials.gov Identifier: NCT00216632 - Active, not recruiting
  Psychotic Disorders; Schizophrenia
  
• Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in the Maintenance Therapy of Patients With Schizophrenia
  ClinicalTrials.gov Identifier: NCT00088491 - Completed
  Schizophrenic Disorders
  
• Double-Blind Trial of Olanzapine in Patients with Manic or Mixed Episode of Bipolar I Disorder
  ClinicalTrials.gov Identifier: NCT00129220 - Recruiting
  Manic or mixed episode associated with bipolar I disorder
  
• Depakote ER plus an atypical antipsychotic vs. an atypical antipsychotic alone in the treatment of schizophrenia
  ClinicalTrials.gov Identifier: NCT00073164 - Completed
  Schizophrenia
  
• The Effect of a Weight Management Program During Treatment With Olanzapine
  ClinicalTrials.gov Identifier: NCT00169702 - Recruiting
  Schizophrenia
  
• Short Term Rescue Study of Olanzapine
  ClinicalTrials.gov Identifier: NCT00186017 - Recruiting
  Bipolar Disorders
  
• An Evaluation of Divalproex Vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder
  ClinicalTrials.gov Identifier: NCT00221481 - Active, not recruiting
  Bipolar Disorder
  
• Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
  ClinicalTrials.gov Identifier: NCT00176436 - Recruiting
  Schizophrenia
  
• 3 Fixed Dosages of Extended Release OROS Paliperidone and Olanzapine in the Treatment of Subjects with Schizophrenia
  ClinicalTrials.gov Identifier: NCT00078039 - Active, not recruiting
  Schizophrenia
  
• Extended Release OROS Paliperidone in Treatment of Schizophrenia (double blind, placebo-controlled trial, with Olanzapine arm)
  ClinicalTrials.gov Identifier: NCT00083668 - Active, not recruiting
  Schizophrenia
  
• Oxycodone-Naloxone Prolonged Release Tablets in Relieving Opioid-Related Constipation
  ClinicalTrials.gov Identifier: NCT00412100 - Active, not recruiting
  Pain
  
• Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine
  ClinicalTrials.gov Identifier: NCT00401973 - Recruiting
  Schizophrenia; Schizoaffective Disorders
  
• Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills
  ClinicalTrials.gov Identifier: NCT00223418 - Active, not recruiting
  Schizophenia Disorder; Schizoaffective Disorder
  
• Treatment and Outcome of Early Onset Bipolar Disorder
  ClinicalTrials.gov Identifier: NCT00048802 - Active, not recruiting
  Bipolar Disorder
  
• An Open-Label Evaluation of the Dose Proportionality of OROS® Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg
  ClinicalTrials.gov Identifier: NCT00398957 - Active, not recruiting
  Analgesia
  
• Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism
  ClinicalTrials.gov Identifier: NCT00287820 - Recruiting
  Schizophrenia; Diabetes; Metabolic Syndrome; Hyperglycemia
  
• Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
  ClinicalTrials.gov Identifier: NCT00036088 - Completed
  Schizophrenia
  
• Olanzapine versus Placebo in the Treatment of Adolescents with Schizophrenia
  ClinicalTrials.gov Identifier: NCT00051298 - Completed
  Schizophrenia
  
• Phase III Study to Assess the Long Term Efficacy, Carry-Over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets
  ClinicalTrials.gov Identifier: NCT00418379 - Active, not recruiting
  Allergy
  
• Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets
  ClinicalTrials.gov Identifier: NCT00166842 - Active, not recruiting
  Transplantation; Kidney Transplantation; Immunosuppression
  
• Long-Term Administration Study of SND 919 Tablets in Parkinson's Disease
  ClinicalTrials.gov Identifier: NCT00274131 - Active, not recruiting
  Parkinson Disease
  
• Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Risperidone and Olanzapine.
  ClinicalTrials.gov Identifier: NCT00149955 - Recruiting
  Schizophrenia; Dual Diagnosis; Schizoaffective Disorder; Psychotic Disorder; Substance Abuse; Cannabis Abuse
  
• Energy Homoeostasis Under Treatment with Atypical Antipsychotics
  ClinicalTrials.gov Identifier: NCT00148564 - Recruiting
  Schizophrenia
  
• Olanzapine Treatment of Patients With Bipolar I Disorder
  ClinicalTrials.gov Identifier: NCT00510146 - Recruiting
  Depression, Bipolar
  
• Changes in the Immune Response and Skin Reactivity of Grass Pollen Allergic Patients Treated With ALK Grass Tablets
  ClinicalTrials.gov Identifier: NCT00413556 - Active, not recruiting
  Allergy
  
• Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients with Schizophrenia and Schizoaffective Disorder
  ClinicalTrials.gov Identifier: NCT00090012 - Completed
  Schizophrenia
  
• An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients
  ClinicalTrials.gov Identifier: NCT00520507 - Recruiting
  Bipolar Disorder, Depression; Depressive Disorder, Major
  
• BMI and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine.
  ClinicalTrials.gov Identifier: NCT00312598 - Recruiting
  Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Mood Disorders With Psychotic Features
  
• A Study of Relapse Prevention and the Effectiveness of Long-Acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schiozaffective Disorder
  ClinicalTrials.gov Identifier: NCT00216476 - Active, not recruiting
  Schizophrenia; Psychotic Disorders
  
• A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain
  ClinicalTrials.gov Identifier: NCT00410878 - Active, not recruiting
  Analgesics, Opioid.; Pain
  
• Treating Drug-Resistant Childhood Schizophrenia
  ClinicalTrials.gov Identifier: NCT00048828 - Recruiting
  Schizophrenia
  
• Switching Medication to Treat Schizophrenia
  ClinicalTrials.gov Identifier: NCT00044655 - Recruiting
  Schizophrenia
  
• Study of Amantadine for Weight Stabilization During Olanzapine Treatment
  ClinicalTrials.gov Identifier: NCT00287352 - Recruiting
  Psychotic Disorder; Schizophreniform Disorder; Schizophrenia; Schizoaffective Disorder
  
• Olanzapine versus Aripiprazole in the Treatment of Acutely Ill Patients with Schizophrenia
  ClinicalTrials.gov Identifier: NCT00103571 - Completed
  Schizophrenia
  
• The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features
  ClinicalTrials.gov Identifier: NCT00035321 - Completed
  Depressive Disorders
  
• Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B
  ClinicalTrials.gov Identifier: NCT00324961 - Active, not recruiting
  Chronic Hepatitis B
  
• A Study of the Efficacy and Safety of Long-Acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia
  ClinicalTrials.gov Identifier: NCT00240708 - Active, not recruiting
  Schizophrenia
  
• Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
  ClinicalTrials.gov Identifier: NCT00355082 - Active, not recruiting
  Epilepsy, Partial
  
• 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the First 6-Month Trial.
  ClinicalTrials.gov Identifier: NCT00174265 - Recruiting
  Schizophrenia
  
• 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the First 6-Month Trial
  ClinicalTrials.gov Identifier: NCT00265343 - Recruiting
  Schizophrenia
  
• Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment
  ClinicalTrials.gov Identifier: NCT00428168 - Recruiting
  Weight Gain
  
• Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
  ClinicalTrials.gov Identifier: NCT00202293 - Recruiting
  Bipolar Disorder; Schizoaffective Disorder
  
• Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder
  ClinicalTrials.gov Identifier: NCT00034580 - Completed
  Bipolar Disorder
  
• Schizophrenia Risperidone vs Olanzapine Study HGMN
  ClinicalTrials.gov Identifier: NCT00373321 - Recruiting
  Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
  
• Lopinavir Capsules to Kaletra or Invirase Tablets
  ClinicalTrials.gov Identifier: NCT00438152 - Recruiting
  HIV Infections
  
• Olanzapine Versus Placebo in the Treatment of Mania in Adolescents with Bipolar I Disorder
  ClinicalTrials.gov Identifier: NCT00050206 - Completed
  Bipolar Disorder
  
• Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets
  ClinicalTrials.gov Identifier: NCT00553865 - Recruiting
  Essential Hypertension
  
• Study Comparing Olanzapine with Haloperidol for the Relief of Nausea and Vomitting in Patients with Advanced Cancer
  ClinicalTrials.gov Identifier: NCT00124930 - Recruiting
  Refractory Nausea
  
• Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine
  ClinicalTrials.gov Identifier: NCT00512070 - Recruiting
  Schizophrenia; Schizoaffective Disorder; Obesity; Metabolic Syndrome
  
• Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1
  ClinicalTrials.gov Identifier: NCT00396149 - Recruiting
  Allergy
  
• Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
  ClinicalTrials.gov Identifier: NCT00088049 - Completed
  Schizophrenia
  
• Olanzapine Augmentation Therapy in Treatment-Resistant Depression: a Double-Blind Placebo-Controlled Trial
  ClinicalTrials.gov Identifier: NCT00273624 - Recruiting
  Therapy-Resistant Depression
  
• A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity Disorder
  ClinicalTrials.gov Identifier: NCT00326300 - Active, not recruiting
  Attention Deficit Hyperactivity Disorder
  
• Comparison of Intramuscular Olanzapine Depot with Placebo in the Treatment of Patients with Schizophrenia
  ClinicalTrials.gov Identifier: NCT00088478 - Completed
  Schizophrenia
  
• Olanzapine in the Treatment of Patients With Anorexia Nervosa
  ClinicalTrials.gov Identifier: NCT00260962 - Recruiting
  Anorexia Nervosa
  
• Olanzapine Compared to Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar I Disorder
  ClinicalTrials.gov Identifier: NCT00094549 - Completed
  Bipolar Disorder
  
• A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients
  ClinicalTrials.gov Identifier: NCT00402324 - Recruiting
  Bipolar I Disorder
  
• Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
  ClinicalTrials.gov Identifier: NCT00190749 - Recruiting
  Schizophrenia; Schizoaffective Disorder
  
• Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis
  ClinicalTrials.gov Identifier: NCT00409409 - Recruiting
  Allergy
  
• Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.
  ClinicalTrials.gov Identifier: NCT00356915 - Active, not recruiting
  Onychomycosis of the Toenail
  
• PET Imaging and Olanzapine Treatment in Borderline Personality Disorder
  ClinicalTrials.gov Identifier: NCT00275301 - Recruiting
  Borderline Personality Disorder
  
• Pilot Study of Topiramate and Olanzapine in the Prevention of Weight Gain in Children and Adolescents With Bipolar Disorder
  ClinicalTrials.gov Identifier: NCT00394095 - Recruiting
  Bipolar Disorder; Weight Gain
  
• Olanzapine Versus Active Comparator in the Treatment of Depression in Patients with Schizophrenia
  ClinicalTrials.gov Identifier: NCT00034801 - Completed
  Depression; Schizophrenia; Schizoaffective Disorder
  
• Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain
  ClinicalTrials.gov Identifier: NCT00463047 - Recruiting
  Chronic Pain
  
• Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients
  ClinicalTrials.gov Identifier: NCT00541385 - Recruiting
  Malaria
  
• Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
  ClinicalTrials.gov Identifier: NCT00348309 - Recruiting
  Alzheimer Disease
  
• Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever: a Pilot Study.
  ClinicalTrials.gov Identifier: NCT00135629 - Active, not recruiting
  Seasonal Allergic Rhinoconjunctivitis
  
• Medication Treatment for Psychotic Depression
  ClinicalTrials.gov Identifier: NCT00056472 - Recruiting
  Depression; Major Depressive Disorder
  
• Population Pharmacokinetic Study in Adolescent Patients with Schizophrenia or Bipolar I Disorder with Olanzapine
  ClinicalTrials.gov Identifier: NCT00113594 - Completed
  Schizophrenia; Bipolar Disorder
  
• Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With ITP
  ClinicalTrials.gov Identifier: NCT00441090 - Recruiting
  Chronic Idiopathic Thrombocytopenic Purpura (ITP)
  
• Efficacy and Safety of Olanzapine in Patients with Borderline Personality Disorder
  ClinicalTrials.gov Identifier: NCT00088036 - Completed
  Borderline Personality Disorder
  
• Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
  ClinicalTrials.gov Identifier: NCT00100776 - Completed
  Schizophrenia; Schizoaffective Disorder
  
• Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
  ClinicalTrials.gov Identifier: NCT00086203 - Active, not recruiting
  Chronic Lymphocytic Leukemia
  
• The Effects on Thinking of Risperidone and Olanzapine
  ClinicalTrials.gov Identifier: NCT00108368 - Completed
  Schizophrenia; Psychotic Disorders
  
• The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women
  ClinicalTrials.gov Identifier: NCT00141557 - Recruiting
  Menopause
  
• Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder
  ClinicalTrials.gov Identifier: NCT00266630 - Recruiting
  Manic or Mixed Episode Associated With Bipolar I Disorder
  
• A Phase 3, Randomized, Open-Label, Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice-Daily Administration, When Co-Administered With NRTIs in Antiretroviral Naive HIV-1 Infected Subjects
  ClinicalTrials.gov Identifier: NCT00262522 - Active, not recruiting
  HIV Infection
  
• Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
  ClinicalTrials.gov Identifier: NCT00348140 - Recruiting
  Alzheimer's Disease